MedTrace Logo

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

NCT04146285 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-07-10

No results posted yet for this study

Summary

This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.

Conditions

  • Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG

BAT4406F

Open-label dose escalation starting from 20mg. Route of administration: intravenous infusion.

Sponsors & Collaborators

Principal Investigators

  • Xiangjun Chen · Huashan Hospital

  • Jing Zhang · Huashan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-03-13
Completion
2023-12-25

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04146285 on ClinicalTrials.gov